The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jul. 28, 2015

Filed:

Aug. 06, 2009
Applicants:

Ingegerd Hellstrom, Seattle, WA (US);

Jeffrey A. Ledbetter, Shoreline, WA (US);

Martha Hayden-ledbetter, Shoreline, WA (US);

Inventors:

Ingegerd Hellstrom, Seattle, WA (US);

Jeffrey A. Ledbetter, Shoreline, WA (US);

Martha Hayden-Ledbetter, Shoreline, WA (US);

Assignee:
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07K 14/435 (2006.01); C07K 19/00 (2006.01); C07K 14/81 (2006.01); C07K 16/18 (2006.01); C07K 16/30 (2006.01); C07K 16/40 (2006.01); G01N 33/574 (2006.01); G01N 33/53 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
C07K 14/811 (2013.01); C07K 16/18 (2013.01); C07K 16/30 (2013.01); C07K 16/3069 (2013.01); C07K 16/40 (2013.01); G01N 33/57449 (2013.01); G01N 33/57488 (2013.01); A61K 2039/505 (2013.01); C07K 2319/00 (2013.01); C07K 2319/30 (2013.01);
Abstract

The invention is directed to compositions and methods for the detection of a malignant condition, and relates to the discovery of soluble and cell surface forms of HE4a polypeptides, including HE4a that is overexpressed in ovarian carcinomas. In particular the invention provides a nucleic acid sequence encoding HE4a, and also provides a method of screening for the presence of a malignant condition in a subject by detecting reactivity of an antibody specific for a HE4a polypeptide with a molecule naturally occurring in soluble and/or cell surface form in a sample from such a subject, and by hybridization screening using an HE4a nucleotide sequence, as well as other related advantages.


Find Patent Forward Citations

Loading…